DLGAP1-AS2 promotes estrogen receptor signalling and confers tamoxifen resistance in breast cancer.
Xiaoli LiangYang ZhaoZeng FangNan ShaoDuanyang ZhaiMengmeng ZhangLiang YuYawei ShiPublished in: Molecular biology reports (2022)
Our research clarified that DLGAP1-AS2 promotes ER signalling to induce tamoxifen resistance and that targeting DLGAP1-AS2 might be a promising strategy to overcome tamoxifen resistance in breast cancer.